Dupilumab-induced conjunctivitis is an inflammation of the eye’s conjunctiva (the clear tissue covering the white part of the eye and the inside of the eyelids) that starts after a person begins treatment with dupilumab, a biologic drug used most commonly to treat moderate to severe atopic dermatitis and some other allergic conditions. Dupilumab works by blocking two immune signaling proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key drivers of the type 2 (Th2) allergic inflammation underlying atopic dermatitis. While this blockade improves skin disease, in a subset of patients it leads to eye surface problems, the most frequent being conjunctivitis. This phenomenon is usually grouped under the broader term Dupilumab-Associated Ocular Surface Disease (DAOSD), of which conjunctivitis is the most common manifestation.PMC Nature Wiley Online Library
Dupilumab-induced conjunctivitis is an eye inflammation that can happen in some people being treated with dupilumab, a biologic drug used mostly for moderate-to-severe atopic dermatitis. Dupilumab works by blocking interleukin-4 and interleukin-13 signaling, which calms skin inflammation but, in a subset of patients, causes unexpected irritation on the eye surface. This eye reaction ranges from mild redness and tearing to more serious inflammation with eyelid changes, cicatrization (scarring), and symptoms of dry eye. Because the constellation of findings often involves the eyelids, tear film, and conjunctiva, experts sometimes group it under the broader term dupilumab-associated ocular surface disease (DAOSD).PMC
Mechanistically, blocking IL-13 may reduce conjunctival goblet cell number and mucin production, weakening the protective tear layer and exposing the ocular surface to irritation. Additional immune shifts and barrier disruption appear to contribute. Patients with a history of preexisting ocular surface disease or severe atopic dermatitis are at higher risk.PMCMedical Journals Sweden Incidence varies, but ophthalmologist-confirmed conjunctivitis has been reported in roughly 15–33% of atopic dermatitis patients on dupilumab in different series.Jaci In PracticeWiley Online Library
The exact reason why blocking IL-4/IL-13 causes conjunctivitis is not fully understood, but several immune shifts, changes in the ocular surface environment, and pre-existing ocular surface vulnerabilities combine to produce this side effect. While many cases are mild and manageable without stopping dupilumab, some can progress to more serious inflammation, scarring, or chronic discomfort if not recognized and treated early.PMCWiley Online LibraryJAAD
Types / Clinical Presentations of Dupilumab-Induced Conjunctivitis
Dupilumab-induced conjunctivitis is not a single uniform appearance; multiple types or patterns of conjunctival and ocular surface involvement have been described. Understanding these helps tailor diagnosis and treatment.
Mild Non-specific Conjunctivitis: The most common form, with redness, mild irritation, and tearing. It often resembles simple allergic or irritative conjunctivitis.Wiley Online Library
Follicular Conjunctivitis: Characterized by small lymphoid follicles, especially on the lower tarsal conjunctiva; suggests immune activation with a lymphoid component.Nature
Papillary Conjunctivitis: Raised, red papillae on the tarsal conjunctiva causing a cobblestone appearance, often associated with chronic inflammation.Wiley Online Library
Cicatrizing Conjunctivitis: A rarer but more serious form where scarring (fibrosis) of conjunctiva occurs, potentially leading to eyelid malposition, symblepharon (adhesions), and vision impact.PMCScienceDirect
Atopic Keratoconjunctivitis–like Presentation: In some patients the ocular surface findings resemble atopic keratoconjunctivitis, with both conjunctival and corneal involvement, increasing risk of vision issues.ScienceDirect
Dry Eye–Dominant Conjunctivitis: Tear film instability and reduced mucin from goblet cell alterations produce a dry, gritty conjunctivitis picture.PMC
Blepharitis-Associated Conjunctivitis: Inflammation of eyelid margins (blepharitis) coexists and aggravates conjunctival inflammation, often through meibomian gland dysfunction.JAAD
Periocular Dermatitis with Secondary Conjunctival Irritation: Skin inflammation around the eyes can spill over or secondarily inflame the conjunctiva.Nature
Mixed Phenotypes: Many patients have overlapping features, such as follicular changes plus tear-film driven irritation; recognizing the dominant component guides therapy.Wiley Online Library
Causes / Risk Factors
The term “causes” here includes predisposing risk factors, biological mechanisms, and environmental contributors that together make conjunctivitis more likely in a patient taking dupilumab.
Underlying Severe Atopic Dermatitis: Higher baseline skin disease severity (e.g., EASI score ≥28) increases risk, possibly because the immune milieu and ocular surface are already disrupted.Frontiers
History of Prior Conjunctivitis or Ocular Surface Disease: Patients with previous eye inflammation are more prone to developing dupilumab-associated ocular issues.Frontiers
Baseline Elevated IgE Levels: High IgE is a marker of allergic drive and has been correlated with increased ocular side effects, reflecting a susceptible immune environment.EyeWikiDermatology Times
Elevated Baseline Eosinophils: Increased eosinophil counts (systemically or locally) may reflect an immune state that predisposes to ocular inflammation when IL-4/IL-13 are blocked.PMC
Immune Shift Toward IL-17 Pathways: Blocking IL-4/IL-13 can unmask or shift toward IL-17–mediated pathways, which may alter ocular surface homeostasis and contribute to inflammation.Nature
Altered Conjunctival Transcriptomic Profile: Some people have pre-existing gene expression patterns in conjunctival cells that make them prone to developing ocular surface disease when treated with dupilumab.ScienceDirect
Goblet Cell Dysfunction or Loss: IL-13 contributes to mucin regulation; its inhibition may reduce goblet cell function or density, destabilizing the tear film and making the conjunctiva more easily inflamed.PMC
Tear Film Instability: Secondary to mucin deficiency or meibomian gland dysfunction, unstable tears expose and irritate the conjunctiva.JAAD
Meibomian Gland Dysfunction / Blepharitis: Chronic eyelid margin inflammation impairs lipid layer of tear film, promoting surface inflammation.JAAD
Ocular Surface Microbiome Changes: Shifts in bacterial or Demodex colonization, possibly through immune modulation, can irritate or infect the surface, exacerbating conjunctivitis.Nature
Environmental Allergens or Irritants: Pollen, dust, smoke, or low humidity can stress the surface that is already vulnerable from immune shifts. (General pathophysiologic understanding; exacerbates underlying susceptibility.)
Contact Lens Use: Foreign material on an already sensitive surface increases mechanical irritation and risk of conjunctival inflammation. (Clinical correlation with ocular surface disease aggravating factors.)
Poor Eyelid Hygiene: Accumulation of debris or pathogenic organisms on lids elevates baseline inflammation.JAAD
Age-related Ocular Surface Changes: Older age has been associated independently with higher risk in some risk models, possibly due to diminished tear production or surface resilience.Frontiers
Rapid or Strong Clinical Response of Skin Disease: Paradoxically, some data suggest that less severe ocular events happen in full skin responders, implying partial or differential immune modulation may influence risk; incomplete modulation may destabilize local ocular immunity.PMC
Previous Use of Topical or Systemic Eye Medications: Prior exposure to drops or steroids may alter baseline conjunctival immunity or mask early signs.Dermatology Times
Genetic Predisposition: Underlying genetic differences in immune regulation (implied by transcriptomic susceptibility) can act as a cause.ScienceDirect
Disruption of Ocular Barrier Proteins: Dupilumab may indirectly affect epithelial barrier maintenance on the ocular surface, making it more permeable to irritants. (Inference from its effects on skin barrier and similar pathways; mechanism extrapolated from the broader biology of IL-4/IL-13 blockade.)
Subclinical Viral or Bacterial Colonization: Pre-existing low-grade infections can flare or become symptomatic in the context of immune modulation. (Clinical rationale, often ruled out by testing.)
Concurrent Systemic Allergic State or Atopy: Other allergic conditions (e.g., allergic rhinitis, asthma) indicate systemic type 2 immune skewing and are part of the atopic milieu that renders the ocular surface more fragile. (Generalized understanding, consistent with atopic disease clustering.)
Symptoms of Dupilumab-Induced Conjunctivitis
Patients with conjunctivitis caused or unmasked by dupilumab commonly describe a constellation of eye-related complaints. The most frequent symptoms include:
Redness: The white part of the eye or inner eyelid appears pink or red due to increased blood flow and inflammation.Wiley Online Library
Itching: A scratchy, uncomfortable feeling often prompting rubbing, which can worsen inflammation.Wiley Online Library
Tearing / Watery Eyes: Reflex tearing in response to irritation or surface instability.Wiley Online Library
Dryness / Grittiness: Feeling of sand or dryness, commonly from tear film disruption.PMC
Foreign Body Sensation: Feeling like something is in the eye even when nothing is present, due to surface irregularity.Wiley Online Library
Burning or Stinging: A mild-to-moderate discomfort from inflammatory mediators on the ocular surface.Wiley Online Library
Mucous Discharge / Stickiness: Thick or stringy material adhering to eyelashes or eyelids, reflecting conjunctival response.Taylor & Francis Online
Blurred Vision: Often transient, from tear film instability or surface irregularity interfering with light transmission.ScienceDirect
Light Sensitivity (Photophobia): Increased sensitivity to bright light due to surface inflammation and irritation.Wiley Online Library
Eyelid Swelling or Edema: Puffiness around the eye from inflammatory fluid accumulation or associated blepharitis.Nature
Eyelid Dermatitis / Redness: Skin inflammation touching the ocular surface, often part of the broader ocular surface disease.Nature
Sense of Eye Fatigue or Heaviness: Subjective tiredness or discomfort, especially after reading or screen use. (Common with chronic ocular surface irritation.)
Increased Blink Frequency or Incomplete Blinks: Reflex or compensatory changes due to surface discomfort. (Clinical observation from ocular surface disease literature.)
Discomfort with Contact Lens Wear: Eyes become intolerant to lenses that were previously well tolerated, because of heightened surface sensitivity. (Expected based on disrupted surface and inflammation.)
Stringy or Filamentary Keratopathy Symptoms: In more severe surface disease, tiny filaments may form causing pulling sensation—this overlaps with keratoconjunctivitis features.ScienceDirect
Diagnostic Tests for Dupilumab-Induced Conjunctivitis
(Organized into categories: Physical Exam, Manual/Functional, Laboratory/Pathological, Electrodiagnostic/Surface Function, and Imaging)
A. Physical Examination (Core clinical evaluation)
Slit Lamp Examination: Microscopic inspection of conjunctiva, cornea, eyelids, and tear film. This is essential to identify conjunctival hyperemia, follicles, papillae, epithelial defects, and early scarring.ScienceDirect
External Inspection and Eyelid Margin Assessment: Visual and tactile check for blepharitis, eyelid inflammation, meibomian gland orifice changes, and periocular dermatitis.JAAD
Visual Acuity Measurement: Document baseline and any blurred vision due to surface irregularity or inflammation.ScienceDirect
Conjunctival Hyperemia Grading: Subjective but standardized assessment of redness extent and severity. (Common ophthalmic clinical practice.)
Tear Meniscus Evaluation: Observation of tear volume at the lower eyelid margin; shows tear film adequacy. (Part of ocular surface exam.)
B. Manual / Functional Surface Tests
Tear Break-Up Time (TBUT): After fluorescein is placed, the time until dry spots appear; indicates tear film stability. A short TBUT suggests instability contributing to conjunctival irritation.PMC
Schirmer Test: Measures the basic tear production using filter paper under the lower eyelid; low wetting suggests aqueous deficiency.PMC
Ocular Surface Staining (Fluorescein, Lissamine Green, Rose Bengal): These dyes highlight epithelial damage on the conjunctiva or cornea, indicating inflammation or dryness.PMC
Meibomian Gland Expression / Evaluation: Manual pressure on eyelids to assess quality of lipid secretion, which affects tear stability.JAAD
Blink Rate and Completeness Assessment: Observing blinking patterns that can reflect compensatory or dysfunctional surface maintenance. (Clinical observation used in ocular surface disease evaluation.)
C. Laboratory and Pathological Tests
Conjunctival Impression Cytology: Sampling superficial conjunctival cells to assess goblet cell density and inflammatory cell infiltration; helps demonstrate surface alteration and chronic inflammation.PMC
Conjunctival Swab for Culture and PCR: To rule out superimposed infectious conjunctivitis (bacterial, viral) which can mimic or coexist with dupilumab-induced conjunctivitis.ScienceDirect
Allergy Testing (Skin Prick or Specific IgE): To detect coexisting allergic conjunctivitis triggers that might confound the presentation. (Relevant because atopic background is common.)Dermatology Times
Tear Film Cytokine Analysis: Research or advanced clinical settings may measure cytokines (e.g., IL-17, other inflammatory mediators) to understand immune shifts on the ocular surface.Nature
Tear Osmolarity Measurement: Elevated osmolarity is an objective sign of ocular surface stress and dry eye contributing to conjunctival discomfort. (Standard in surface disease workup.)
Demodex or Microbiome Evaluation (e.g., Lash Sampling): To detect abnormal colonization (like Demodex) that can worsen or mimic conjunctivitis; relevant given proposed microbiome contributions.Nature
Peripheral Blood Eosinophil Count / Total IgE: Provides systemic context of atopy; while not diagnostic of conjunctivitis itself, high levels correlate with risk and help in holistic assessment.FrontiersEyeWiki
D. Electrodiagnostic or Sensory / Functional Tests
Corneal / Conjunctival Sensitivity Testing (Esthesiometry): Devices like the Cochet-Bonnet esthesiometer measure surface nerve function; altered sensitivity may accompany chronic inflammation and contribute to symptomatology. (Functional ocular surface test.)
In Vivo Confocal Microscopy (Nerve & Cell Assessment): Though more advanced, this allows visualization of corneal nerves and inflammatory cell infiltrates; can detect chronic surface changes affecting sensation. (Blends imaging and functional assessment; helps in research/complex cases.)ScienceDirect
E. Imaging
Anterior Segment Optical Coherence Tomography (AS-OCT): Imaging the conjunctiva and cornea to detect early scarring (in cicatrizing cases), tear film thickness, and structural surface disruptions; useful for monitoring progression.ScienceDirect
Meibography (Infrared Imaging of Meibomian Glands): Visualizes gland dropout or changes contributing to tear instability.JAAD
High-Resolution Anterior Segment Photography: Documenting external findings, eyelid margin pathology, conjunctival patterns, and following therapy response. (Standard ophthalmic documentation.)
Tear Film Thickness Imaging (e.g., OCT-based dynamic tear assessment): Evaluates tear layer integrity, helpful in complex or refractory ocular surface irritation. (Emerging method consistent with tear film evaluation.)
Infrared Eyelid Imaging / Lid Margin Thermography: Assesses inflammation or dysfunction of eyelid glands contributing to surface disease; used in advanced dysfunction workups.
Non-Pharmacological Treatments (Therapies and Others)
Eyelid hygiene with warm compresses: Gently applying warm compresses to the eyelids loosens debris and melts abnormal oil from meibomian glands, improving tear film quality. Purpose is to reduce blepharitis-like inflammation that often accompanies ocular surface disease. Mechanism: heat liquefies inspissated meibum, facilitating gland expression and decreasing bacterial biofilm.Nature
Gentle lid scrubs: Using mild, non-irritating cleansers (e.g., diluted baby shampoo or commercially available eyelid cleansers) cleans eyelid margins of debris and inflammatory skin scales. Purpose: control lid margin inflammation. Mechanism: mechanical removal of irritants and bacterial colonization that can drive surface inflammation.PMC
Artificial tears (preservative-free): Frequent use of preservative-free lubricating drops keeps the eye surface moist, dilutes inflammatory mediators, and substitutes for deficient mucin/water layer. Purpose: symptom relief and barrier support. Mechanism: replenishes tear film volume and reduces friction on the conjunctiva.JAADSMW
Blinking exercises / behavioral modification: Encouraging full, regular blinks (especially during screen use) helps spread tears evenly and reduces tear evaporation. Purpose: maintain tear film integrity. Mechanism: mechanical redistribution of tears to prevent dry spots.JAAD
Environmental humidification: Using humidifiers in dry indoor air prevents excessive tear evaporation. Purpose: reduce dry eye symptoms that exacerbate conjunctival irritation. Mechanism: increases ambient humidity, slowing tear film breakup.JAAD
Avoiding eye rubbing: Rubbing can worsen surface inflammation, break fragile epithelium, and introduce microbes. Purpose: prevent mechanical exacerbation. Mechanism: reduces microtrauma and secondary inflammation.JAAD
Reducing allergen exposure: Minimizing airborne allergens (dust, pet dander, pollen) and using air filters lowers conjunctival allergic stimulation that can compound inflammation. Purpose: lessen overlapping allergic conjunctivitis triggers. Mechanism: decreases histamine and mast cell activation in conjunctiva.JAAD
Limiting contact lens use during flares: Contact lenses can irritate an already fragile ocular surface. Purpose: give the eye a break while inflammation is active. Mechanism: removing mechanical foreign body stress and potential microbe reservoirs.Nature
Screen-time breaks and ergonomic adjustments: Prolonged screen use reduces blink rate, worsening surface dryness. Purpose: restore normal blinking and tear distribution. Mechanism: behavioral interruption to prevent tear film breakup.JAAD
Cold compresses for itching: Applying cool compresses can relieve the sensation of itching or irritation without medications. Purpose: symptomatic relief. Mechanism: vasoconstriction and reduced nerve activation temporarily dulls itch.JAAD
Hydration and systemic moisture support: Adequate water intake supports mucosal hydration systemically. Purpose: baseline support for tear production. Mechanism: maintains overall mucosal secretions. (General supportive measure; inferred from dry eye pathophysiology.)Ajo
Eyelid massage: Manual gentle massage of eyelids after warm compresses helps express gland contents in meibomian dysfunction. Purpose: improve lipid layer. Mechanism: mechanical mobilization of meibum.ResearchGate
Prophylactic use of artificial tears before symptoms: Starting lubrication early when beginning dupilumab if risk factors exist. Purpose: preempt tear film degradation. Mechanism: buffering early inflammatory changes on the surface.SMW
Ocular surface protective eyewear: Using wraparound glasses outdoors reduces wind and particulate exposure. Purpose: lessen evaporative stress. Mechanism: physical barrier limiting tear evaporation and irritant contact.JAAD
Sleep hygiene and eyelid closure strategies: Ensuring full eyelid closure at night prevents exposure-related surface drying. Purpose: nocturnal ocular surface protection. Mechanism: maintains continuous tear coverage. (Common dry eye preventative concept.)JAAD
Avoiding preservative-containing drops when possible: Chronic preservatives can irritate the surface. Purpose: reduce chemical irritation. Mechanism: eliminates repetitive toxic insult from preservatives.JAAD
Early ophthalmologic screening and baseline assessment: Before starting dupilumab, having an eye exam identifies preexisting risk and allows early intervention. Purpose: risk stratification. Mechanism: identifies and treats baseline ocular surface disease.Medical Journals Sweden
Staged dupilumab initiation with ocular monitoring: In those at high risk, close follow-up in the initial months catches early conjunctivitis. Purpose: early capture and treatment. Mechanism: prevents progression by prompt care.Wiley Online Library
Patient education about symptoms: Teaching patients to report redness, tearing, itch, or vision change early leads to faster management. Purpose: reduce delays in care. Mechanism: prompt symptom recognition. (Best practice recommended by consensus articles.)anndermatol.org
Modification of topical skin regimens around the eyes: Avoid irritant creams or topical corticosteroids directly on lids without ophthalmic guidance. Purpose: reduce periocular irritation that may aggravate ocular surface. Mechanism: prevents overlapping inflammation from skin products.Nature
Drug Treatments
Topical low-potency corticosteroids (e.g., loteprednol etabonate 0.5% or fluorometholone): Class: corticosteroid. Dosage/Timing: typically started 2–4 times daily for short courses (1–2 weeks) then tapered based on response. Purpose: rapidly reduce conjunctival and eyelid inflammation. Mechanism: suppresses inflammatory cytokines and immune cell infiltration. Side effects: increased intraocular pressure if prolonged, cataract formation with chronic use, risk minimized by using low potency and limited duration.EyeWikiNature
Topical cyclosporine A (e.g., Ikervis 0.1% or Restasis 0.05%): Class: calcineurin inhibitor (immunomodulator). Dosage/Timing: typically 1–2 times daily; often continued long-term. Purpose: reduce chronic surface inflammation and restore goblet cell function. Mechanism: inhibits T-cell activation and inflammatory mediator release, potentially counteracting local immune imbalance from dupilumab. Side effects: transient burning/stinging on instillation.Natureanndermatol.org
Topical tacrolimus ointment (used on eyelid skin): Class: calcineurin inhibitor. Dosage/Timing: applied to eyelid skin (not the eye surface) usually twice daily under ophthalmologist/dermatologist guidance. Purpose: control periocular eczema and lid margin inflammation that contributes to ocular surface irritation. Mechanism: inhibits calcineurin pathway in T-cells, reducing skin inflammation. Side effects: local irritation, rare systemic absorption concerns when used appropriately.Nature
Lifitegrast ophthalmic solution (LFA-1 antagonist): Class: integrin antagonist. Dosage/Timing: usually twice daily. Purpose: reduce ocular surface inflammation, especially when steroids alone are insufficient or for steroid-sparing. Mechanism: blocks lymphocyte function-associated antigen-1 (LFA-1) interaction, decreasing T-cell mediated inflammation. Side effects: dysgeusia (altered taste), eye irritation. Evidence of benefit as add-on in dupilumab-induced inflammation has been reported in case series.JAAD Case Reports
Topical antihistamine/mast cell stabilizers (e.g., olopatadine, ketotifen): Class: antihistamine/mast-cell stabilizer. Dosage/Timing: typically once or twice daily. Purpose: relieve itching and mild allergic-type conjunctival symptoms that coexist or mimic dupilumab-induced irritation. Mechanism: blocks histamine receptors and stabilizes mast cells to limit mediator release. Side effects: mild burning, dry eyes.JAAD
Autologous serum eye drops (used as a biologic topical therapy): Class: biologic growth-factor-rich therapy. Dosage/Timing: typically 4–6 times per day. Purpose: support healing of damaged ocular surface and provide missing trophic factors. Mechanism: serum contains epithelial growth factors, vitamin A, fibronectin, and other proteins that promote epithelial integrity. Side effects: requires careful preparation to avoid contamination; not a conventional “drug” but used in refractory surface disease.JAAD
Topical antibiotic ointment (e.g., erythromycin or bacitracin): Class: antibiotic. Dosage/Timing: usually at night if secondary bacterial colonization or eyelid margin infection is suspected. Purpose: prevent or treat secondary infection complicating conjunctivitis/blepharitis. Mechanism: inhibits bacterial growth on lids and lashes. Side effects: mild irritation or allergic reaction.ResearchGate
Temporary dupilumab discontinuation or dose modification: Class: biologic therapy adjustment. Dosage/Timing: under dermatologist/ophthalmologist coordination when severe ocular surface disease does not respond to local therapy. Purpose: allow the ocular surface to recover from the immune perturbation. Mechanism: reduction of systemic blockade of IL-4/IL-13 to rebalance ocular immune environment. Side effects: potential flare of underlying skin disease.Wiley Online Library
Topical non-steroidal anti-inflammatory drops (off-label/limited use): Class: NSAID. Dosage/Timing: sometimes used short-term for surface discomfort. Purpose: inflammation control when steroid is contraindicated. Mechanism: COX inhibition reducing prostaglandin-mediated inflammation. Side effects: delayed epithelial healing, corneal risk if misused; use cautiously. (Inferred from general ocular surface practice; not first-line in DIOSD.)JAAD
Adjunct preservative-free tear supplements with hyaluronic acid or carboxymethylcellulose: Class: lubricant enhancers. Dosage/Timing: multiple times daily. Purpose: improve retention and tear film stability. Mechanism: polymeric components bind water and form a protective layer. Side effects: minimal; sometimes transient blur.JAAD
Dietary Molecular Supplements
Omega-3 fatty acids (EPA/DHA): Dosage: 1000–3000 mg combined EPA/DHA daily. Function: support tear film lipid layer and reduce inflammation. Mechanism: anti-inflammatory eicosanoid production and modulation of ocular surface cytokines, reducing dry eye and surface inflammation.Ajo
Vitamin A (retinol or beta-carotene precursor): Dosage: dietary intake per RDA (700–900 µg RAE) or under physician guidance for deficiency. Function: maintains conjunctival and corneal epithelial health. Mechanism: essential for mucin-secreting goblet cell function and epithelial differentiation. Deficiency worsens surface integrity.Ajo
Vitamin D: Dosage: 1000–2000 IU daily or based on serum level correction. Function: immune regulation on the ocular surface and reduction of inflammatory dry eye signs. Mechanism: modulates innate and adaptive immune responses, potentially decreasing inflammatory cytokines.Ajo
Vitamin B12: Dosage: 500–1000 mcg daily (oral or sublingual), especially if deficiency suspected. Function: nerve health and possible reduction of neuropathic ocular surface discomfort. Mechanism: supports neuronal repair and may reduce burning sensations in chronic ocular irritation. Evidence is moderate.Ajo
Antioxidants (Vitamins C and E): Dosage: Vitamin C 500–1000 mg, Vitamin E 15 mg daily as part of diet/supplement regimen. Function: protect ocular surface cells from oxidative stress. Mechanism: free radical scavenging to preserve epithelial integrity and reduce inflammation.Ajo
Lutein and zeaxanthin: Dosage: typical supplement combinations (e.g., Lutein 10 mg, Zeaxanthin 2 mg). Function: general ocular health support, especially in maintaining mucosal resilience. Mechanism: antioxidant and anti-inflammatory action in ocular tissues, though data in conjunctivitis is indirect.Ajo
Gamma-linolenic acid (GLA, e.g., from evening primrose or borage oil): Dosage: 500–1000 mg daily (as GLA). Function: modulate inflammatory pathways in ocular surface disease. Mechanism: precursor to anti-inflammatory prostaglandins. Evidence is mixed; used adjunctively in some surface disorders.JAAD
N-acetylcysteine (NAC): Dosage: 600–1200 mg daily (oral) or topical in certain formulations. Function: mucolytic and surface stabilizer. Mechanism: breaks disulfide bonds in abnormal mucus and may support tear film quality; more common in chronic mucous issues.JAAD
Zinc: Dosage: 8–11 mg daily (as part of diet/supplement). Function: supports epithelial healing and immune balance. Mechanism: cofactor in wound healing and regulation of inflammatory mediators.Ajo
Probiotics (gut-eye axis support): Dosage: varies by formulation; common multispecies regimens. Function: modulate systemic immune tone, potentially reducing aberrant surface inflammation. Mechanism: influences systemic cytokine profiles via gut mucosal immune interactions; evidence emerging but not yet definitive for conjunctivitis.ResearchGate
Regenerative / “Hard Immunity” / Stem Cell or Biologic Therapies
Autologous serum eye drops: (Revisited here as regenerative biologic) These provide patient’s own growth factors and immunoglobulins to regenerate a damaged ocular surface. Dosage: several times daily; typically compounded from the patient’s blood. Function: promote epithelial healing, restore tear film components. Mechanism: reinforcement of epithelial cell health via natural trophic factors. Evidence supports use in refractory ocular surface inflammation.JAAD
Platelet-rich plasma (PRP) eye drops: Dosage/Usage: prepared from patient blood, used multiple times daily. Function: similar to serum drops but enriched in platelet-derived growth factors. Mechanism: stimulates cellular proliferation and repair of the ocular surface. Evidence is promising in chronic surface disease as a regenerative therapy.JAAD
Recombinant human nerve growth factor (cenegermin): Class: neurotrophic factor. Dosage: six times daily for 8 weeks (approved for neurotrophic keratitis). Function: regenerates corneal nerve fibers and improves epithelial defects. Mechanism: binds TrkA receptors to support nerve survival and epithelial healing; indirectly helps ocular surface resilience. While not specific to dupilumab conjunctivitis, it represents a regenerative approach when corneal neurotrophic damage coexists.Ajo
Amniotic membrane therapy (e.g., Prokera device or transplant): Class: biological scaffold. Dosage/Procedure: placed on ocular surface for days as a temporary graft. Function: provides anti-inflammatory cytokines and matrix to promote healing and reduce scarring. Mechanism: amniotic membrane contains growth factors and anti-fibrotic proteins that modulate inflammation and aid epithelialization. Used when cicatrization or persistent inflammation endangers surface integrity.Nature
Experimental mesenchymal stem cell (MSC) therapy: Status: investigational. Function: immune modulation and potential tissue repair via paracrine effects. Mechanism: MSCs secrete anti-inflammatory cytokines and growth factors that may reset aberrant ocular surface immunity; current evidence is preclinical or early-phase, so use is limited to clinical trials or specialized centers.ResearchGate
Topical growth factor formulations / combination biologics: These include emerging eyedrops containing epithelial growth factors, hyaluronic acid with added bioactive molecules, or engineered peptides aimed at restoring barrier function. Function: surface regeneration. Mechanism: supply targeted factors to rebuild tight junctions and mucin layer. Evidence is evolving; such preparations are best used under specialist guidance in severe, refractory inflammation.JAAD
Surgical or Procedural Interventions
Symblepharon lysis with mucous membrane graft: Procedure: surgical release of adhesions between the eyelid and eyeball followed by grafting healthy mucosa. Why done: in advanced cicatrizing conjunctivitis from chronic inflammation, adhesions can restrict movement and threaten vision. This restores anatomy and prevents recurrence of scarring.Nature
Punctal occlusion or plugs: Procedure: insertion of small devices or surgical closure of tear drainage openings. Why done: to increase tear retention on the eye surface when dryness contributes to inflammation. Mechanism: reduces tear outflow so lubricants remain longer, helping healing.JAAD
Eyelid margin repair / blepharoplasty for cicatricial changes: Procedure: correcting distorted eyelid anatomy due to chronic inflammation (e.g., entropion, eyelid margin scarring). Why done: to prevent exposure, lid-induced irritation, or misdirected lashes that further damage the ocular surface.Nature
Tarsorrhaphy: Procedure: partial sewing together of the eyelids. Why done: used temporarily to protect severely damaged ocular surfaces by reducing exposure and promoting healing in refractory cases. Mechanism: minimizes evaporation and mechanical trauma.JAAD
Conjunctival biopsy (diagnostic-therapeutic overlap): Procedure: sampling conjunctival tissue. Why done: when atypical scarring, persistent inflammation, or suspicion of other underlying pathology exists; it guides targeted therapy and rules out mimicking diseases. Though primarily diagnostic, it may influence surgical planning.Nature
Preventions
Baseline eye exam before starting dupilumab to assess for existing surface disease and treat it proactively.Medical Journals Sweden
Early and regular eyelid hygiene to minimize lid margin contributors.PMC
Prophylactic use of preservative-free artificial tears in high-risk individuals.SMW
Patient education on early symptoms so they report redness, tearing, or discomfort quickly.anndermatol.org
Avoiding environmental triggers like allergens and dry air through filters and humidification.JAAD
Limiting use of irritant skin products near eyes that could compound ocular inflammation.Nature
Monitoring during early months of dupilumab therapy when most cases arise, with low threshold to start topical therapy.Wiley Online Library
Encouraging healthy systemic nutrition (omega-3, vitamins) to support ocular surface resilience.Ajo
Prompt treatment of minor ocular symptoms to avoid escalation into scarring or chronic disease.JAAD
Co-managing with ophthalmology when risk factors exist (prior ocular disease, severe AD).Medical Journals Sweden
When to See a Doctor
You should see an eye doctor (ophthalmologist) promptly if you develop any of the following while on dupilumab: persistent redness lasting more than a few days despite basic lubrication, eye pain, blurred or decreased vision, sensitivity to light (photophobia), thick or yellow discharge, eyelid changes such as lashes falling out (madarosis), evidence of scarring or sticky lids, significant tearing that does not improve, or if you notice anything new in your vision like spots or halos. Early specialist evaluation can prevent progression to chronic damage or scarring.NatureWiley Online Library
What to Eat and What to Avoid (Dietary Guidance)
For what to eat, focus on nutrients that support inflammation control and ocular surface health: include omega-3-rich fatty fish (salmon, sardines), leafy green vegetables (source of vitamin A precursors and lutein), berries and citrus fruits (vitamin C and antioxidants), nuts and seeds (healthy fats and zinc), whole grains for stable blood sugar, and ensure adequate water intake for systemic hydration. Including foods with vitamin D (fatty fish, fortified dairy) or supplementing if levels are low helps immune balance. Eating a diet rich in natural anti-inflammatory compounds (turmeric in modest amounts, foods high in polyphenols) may also support ocular health.Ajo
For what to avoid, reduce or eliminate high-sugar processed foods that promote systemic inflammation, trans fats and excessive omega-6-rich fried foods, excessive caffeine or alcohol that may dehydrate mucous membranes, and known personal food allergens if you have allergic tendencies that worsen immune activation. Avoid overuse of vitamin A or other fat-soluble vitamins beyond recommended doses without medical supervision, as excess can be harmful. Also limit artificial additives or preservatives that have been reported anecdotally to irritate sensitive individuals.Ajo
Frequently Asked Questions (FAQs)
What is dupilumab-induced conjunctivitis?
It is inflammation of the eye’s surface caused as an unintended side effect of dupilumab therapy, typically in patients treated for atopic dermatitis. It can involve redness, tearing, irritation, and sometimes scarring.PMCWiley Online LibraryWhy does it happen if dupilumab is supposed to reduce inflammation?
Blocking IL-4 and IL-13 can reduce goblet cell function in the conjunctiva, thinning the protective mucin layer, and create an imbalance in local immunity, paradoxically leading to surface irritation.PMCWho is at higher risk?
People with prior ocular surface disease, severe atopic dermatitis, or preexisting dry eye/blepharitis are more likely to develop this condition.Medical Journals SwedenWiley Online LibraryCan the conjunctivitis go away on its own?
Mild cases may improve with supportive care like artificial tears, but many require topical medications. Some patients need long-term drops to keep inflammation controlled.NatureJAADShould I stop dupilumab if I get conjunctivitis?
Not always. Many cases respond to local treatment. Severe or refractory cases might require temporary pause or modification in coordination with your dermatologist and ophthalmologist.Wiley Online LibraryWhat is the first treatment to try?
Start with eyelid hygiene, artificial tears, and prompt ophthalmologic evaluation. If inflammation persists, topical low-potency corticosteroids or immunomodulators like cyclosporine may be added.EyeWikiNatureAre steroids safe for my eyes?
Short courses of low-potency topical steroids are generally safe when monitored. Long-term use without supervision can raise eye pressure or cause cataract, so tapering and follow-up are important.NatureCan supplements help?
Yes, omega-3s, vitamin A (if not excessive), vitamin D, and antioxidants support ocular surface resilience and may reduce inflammation when combined with other treatments.AjoIs this the same as allergic conjunctivitis?
Symptoms may overlap, but the cause is immune modulation from dupilumab rather than classic allergen exposure. Sometimes both coexist, so treatments like antihistamine drops may be helpful.JAADCan it cause permanent damage?
If untreated or if severe inflammation leads to scarring (cicatrization), there can be lasting effects including eyelid distortion. Early treatment minimizes risk.NatureAre there regenerative options if surface is damaged?
Yes. Autologous serum drops, amniotic membrane therapy, and in selected refractory cases even advanced biologics or experimental stem cell approaches are used to heal the surface.JAADResearchGateDo I need an eye doctor or can my dermatologist manage it?
Mild cases might begin with dermatology guidance, but any persistent, painful, vision-affecting, or scarring symptoms warrant referral to an ophthalmologist.Wiley Online LibraryCan I wear contact lenses?
During active inflammation, it is best to avoid contacts to reduce additional irritation and infection risk; resume only after the surface is stabilized.NatureHow quickly does it start after beginning dupilumab?
Onset varies, but many patients develop ocular symptoms within the first few weeks to months; monitoring is highest in early therapy.Wiley Online LibraryCan I prevent it before it starts?
Yes. Baseline eye evaluations, proactive eyelid hygiene, early use of artificial tears, and education on early warning signs all reduce severity and allow earlier intervention.Medical Journals Swedenanndermatol.or
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: August 02, 2025.
